302 related articles for article (PubMed ID: 35341315)
1. Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam.
Alsenani TA; Viviani SL; Kumar V; Taracila MA; Bethel CR; Barnes MD; Papp-Wallace KM; Shields RK; Nguyen MH; Clancy CJ; Bonomo RA; van den Akker F
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0241421. PubMed ID: 35341315
[TBL] [Abstract][Full Text] [Related]
2. Exploring avibactam and relebactam inhibition of
Alsenani TA; Viviani SL; Papp-Wallace KM; Bonomo RA; van den Akker F
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0035023. PubMed ID: 37750722
[No Abstract] [Full Text] [Related]
3. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
Tsivkovski R; Lomovskaya O
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015028
[TBL] [Abstract][Full Text] [Related]
4. Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC β-Lactamase.
Taracila MA; Bethel CR; Hujer AM; Papp-Wallace KM; Barnes MD; Rutter JD; VanPelt J; Shurina BA; van den Akker F; Clancy CJ; Nguyen MH; Cheng S; Shields RK; Page RC; Bonomo RA
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0212421. PubMed ID: 35311523
[TBL] [Abstract][Full Text] [Related]
5.
Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
[TBL] [Abstract][Full Text] [Related]
6. Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae.
Dulyayangkul P; Douglas EJA; Lastovka F; Avison MB
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32660988
[TBL] [Abstract][Full Text] [Related]
7. Mutations in
Haidar G; Clancy CJ; Shields RK; Hao B; Cheng S; Nguyen MH
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223379
[TBL] [Abstract][Full Text] [Related]
8. Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.
Hobson CA; Pierrat G; Tenaillon O; Bonacorsi S; Bercot B; Jaouen E; Jacquier H; Birgy A
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0044722. PubMed ID: 35980232
[TBL] [Abstract][Full Text] [Related]
9. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
[TBL] [Abstract][Full Text] [Related]
10. The Effectiveness of Imipenem-Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase.
Papp-Wallace KM; Barnes MD; Taracila MA; Bethel CR; Rutter JD; Zeiser ET; Young K; Bonomo RA
Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237794
[TBL] [Abstract][Full Text] [Related]
11. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2.
Hemarajata P; Humphries RM
J Antimicrob Chemother; 2019 May; 74(5):1241-1243. PubMed ID: 30753572
[TBL] [Abstract][Full Text] [Related]
12. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring
Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L
mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008
[TBL] [Abstract][Full Text] [Related]
13. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
[TBL] [Abstract][Full Text] [Related]
14. Meropenem/vaborbactam activity
Romanelli F; Stolfa S; Morea A; Ronga L; Prete RD; Chironna M; Santacroce L; Mosca A
Future Microbiol; 2021 Nov; 16():1261-1266. PubMed ID: 34674551
[TBL] [Abstract][Full Text] [Related]
15. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
[TBL] [Abstract][Full Text] [Related]
16. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
[TBL] [Abstract][Full Text] [Related]
17. Effects of KPC Variant and Porin Genotype on the
Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
[TBL] [Abstract][Full Text] [Related]
18. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.
Winkler ML; Papp-Wallace KM; Bonomo RA
J Antimicrob Chemother; 2015 Aug; 70(8):2279-86. PubMed ID: 25957381
[TBL] [Abstract][Full Text] [Related]
19. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
20. Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam.
Satapoomin N; Dulyayangkul P; Avison MB
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0217921. PubMed ID: 35293781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
